Moderna Inc. [NASDAQ: MRNA] closed the trading session at $142.08 on 05/02/22. The day’s price range saw the stock hit a low of $134.82, while the highest price level was $146.45. The company report on April 29, 2022 that Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union.
The filing follows the European Medicines Agency’s Committee for Medicinal Products for Human Use recent decision to adopt a positive opinion recommending marketing authorization for Moderna’s COVID-19 vaccine to include children six years of age and older.
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted for a variation to the conditional marketing authorization (CMA) with the European Medicines Agency (EMA) for the evaluation of a 25 µg two-dose series of Spikevax, the Company’s vaccine against COVID-19, in children six months to under six years of age. Similar requests are underway with international regulatory authorities and are based on a 25 μg two-dose primary series of mRNA-1273.
The stocks have a year to date performance of -44.06 percent and weekly performance of -5.54 percent. The stock has been moved at -58.84 percent over the last six months. The stock has performed -17.52 percent around the most recent 30 days and changed -16.09 percent over the most recent 3-months.
If compared to the average trading volume of 7.10M shares, MRNA reached to a volume of 7766118 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Moderna Inc. [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $234.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Redburn have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 01, 2022. The new note on the price target was released on January 26, 2022, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise from $135 to $180, while BofA Securities kept a Neutral rating on MRNA stock.
The Average True Range (ATR) for Moderna Inc. is set at 10.72, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 3.29. The Price to Book ratio for the last quarter was 4.08, with the Price to Cash per share for the same quarter was set at 25.10. Price to Free Cash Flow for MRNA in the course of the last twelve months was 4.55 with Quick ratio for the last quarter at 1.60.
MRNA stock trade performance evaluation
Moderna Inc. [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.54. With this latest performance, MRNA shares dropped by -17.52% in over the last four-week period, additionally sinking by -58.84% over the last 6 months – not to mention a drop of -23.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 42.17, with the RSI for the last a single of trading hit 41.22, and the three-weeks RSI is set at 43.19 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 155.63, while it was recorded at 141.45 for the last single week of trading, and 266.68 for the last 200 days.
Moderna Inc. [MRNA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of +71.89 and a Gross Margin at +84.53. Moderna Inc.’s Net Margin is presently recorded at +66.27.
Return on Equity for this stock inclined to 146.08, with Return on Assets sitting at 75.78.
Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.80.
Earnings per share (EPS) analysis for Moderna Inc. [MRNA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
Moderna Inc. [MRNA]: Insider Ownership positions
There are presently around $35,184 million, or 63.10% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 45,772,079, which is approximately 8.42% of the company’s market cap and around 2.30% of the total institutional ownership; BLACKROCK INC., holding 27,661,473 shares of the stock with an approximate value of $3.93 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $3.9 billion in MRNA stock with ownership of nearly 0.902% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 595 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 23,155,938 shares. Additionally, 571 investors decreased positions by around 18,118,010 shares, while 114 investors held positions by with 206,362,822 shares. The mentioned changes placed institutional holdings at 247,636,770 shares, according to the latest SEC report filing. MRNA stock had 183 new institutional investments in for a total of 1,671,855 shares, while 225 institutional investors sold positions of 5,075,398 shares during the same period.